The exploratory study to determine optimum dosing of Axitinib (tyrosine kinase inhibitor) with pharmacokinetic analysis for patients with metastatic renal cell carcinoma
Not Applicable
- Conditions
- metastatic renal cell carcinoma
- Registration Number
- JPRN-UMIN000011147
- Lead Sponsor
- Department of Urology, Graduate School of Medicine, Yamaguchi University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) ECOG PS>1 2) sBP>150mmHg or dBP>100mmHg 3) Hb<9.0g/dl 4) neutrophil count<1000/mm3 5) pletelet count<75000/mm3 6) AST/ALT>2.5 ULN 7) total bilirubin>1.5 ULN 8) urine protein>2+ and 2g/day 9) sCre>1.5
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method